Protein kinase C (PKC) is a signal transduction protein that has been proposed to mediate rapid responses to steroid hormones. Previously, we have shown aldosterone directly activates PKC␣ whereas 17␤-estradiol activates PKC␣ and PKC␦; however, neither the binding to PKCs nor the mechanism of action has been established. 
P ROTEIN KINASE C (PKC) belongs to a gene family of serine/threonine protein kinases that are key regulatory enzymes in signal transduction. The PKC family consists of several subfamilies (conventional: ␣, ␤I, ␤II, ␥; novel: ␦, , , ; atypical: , , ) classified according to their requirements for Ca 2ϩ , phospholipids (phosphatidylserine) and diacylglycerol (DAG), or phorbol esters for activation (1) (2) (3) (4) . The conventional and novel PKC isoforms contain an amino-terminal regulatory domain and a carboxyl-terminal catalytic domain (4) . The regulatory domain of conventional PKC isoforms contains two common regions, C1 and C2. The C1 domain mediates DAG and phorbol ester binding through distinct low-and high-affinity binding sites (5) , whereas the C2 domain mediates Ca 2ϩ and phosphatidylserine binding and contains the receptor for activated C kinase binding site (6, 7) . PKC requires acidic phospholipids for its activity, and, in the presence of activators, the enzyme has the highest binding affinity for membranes containing phosphatidylserine. Upon activation, PKC isoforms are translocated to distinct subcellular compartments (membranes) and cell structures to phosphorylate their respective substrates (4, 8) . This compartmentalization is required for the phosphorylation of specific substrates and the regulation of different physiological functions (4, 9) . Preventing PKC translocation from the cytoplasm to membranes inhibits PKC function and the subsequent phosphorylation of specific substrates (7, 9) .
PKC isoforms regulate gene expression and a variety of cellular functions, including growth, differentiation, tumor promotion, aging, and apoptosis (1, 2, 5); however, the biological significance of the heterogeneity in the PKC family is not clear. The distinct subcellular distribution, the presence of several isoforms in the same cell, and differential activation or inhibition by different stimuli suggest that each isoform is involved in the regulation of different functions and has a unique role in the cell (2, 4, 9, 10) .
Steroid hormones regulate cellular processes by binding to intracellular receptors that, in turn, interact with discrete nucleotide sequences to alter gene expression; this process typically takes at least 30-60 min (11, 12) . In contrast, other regulatory actions of steroid hormones are manifested within seconds to a few minutes (13, 14) . These time periods are far too rapid to be due to changes at the genomic level and are therefore termed "nongenomic," to distinguish them from the classical steroid hormone action of regulation of gene expression. The rapid effects of steroid hormones are manifold, ranging from activation of MAPK, adenylyl cyclase, PKC, and G proteins (13) . In some cases, these rapid actions of steroids are mediated through the classical steroid receptor that can also function as a ligand-activated transcription factor, whereas in other instances the evidence suggests that these rapid actions do not involve the classical steroid receptors and are mediated by a putative membrane receptor (13) (14) (15) (16) (17) (18) .
Several studies have described direct activation of different PKC isoforms by steroid hormones. Our laboratory has shown direct activation of PKC␣ by aldosterone and 17␤-estradiol whereas PKC␦ was activated by 17␤-estradiol only (19) . Direct activation of conventional (␣, ␤, and ␥) and PKC isoforms was observed with 1,25-(OH) 2 -vitamin D 3 at physiological concentrations (20) . The adrenal androgen, dehydroepiandrosterone, has been shown to activate conventional and PKC isoforms (21, 22) . Similar results have been observed with glucocorticoids (22, 23) . Therefore, it has been postulated that steroid hormones exert some of their nongenomic effects via direct interaction with PKC isoforms. However, the binding sites and mechanism by which they rapidly regulate PKC activity are not known.
In this work, we have begun the characterization of the biochemical events underlying this regulation. We have previously described direct activation of PKC␣ and PKC␦ by aldosterone and 17␤-estradiol. Here, we have used glutathione S-transferase (GST) fusion PKC mutants to demonstrate the existence and localization of binding sites for these hormones on PKC␣ and PKC␦ isoforms. Using PKC activity assays, we have shown that preincubation of PKC with nanomolar concentrations of aldosterone and 17␤-estradiol increases PKC activity and the level of autophosphorylation.
Taken together, this is the first evidence for a direct, high-affinity binding of aldosterone and 17␤-estradiol to PKC isoforms and the resulting increase in PKC activity. Given the significance of these in vitro results, we hypothesize that aldosterone and 17␤-estradiol might also be involved in directly regulating PKC activity in vivo.
RESULTS

Activation of PKC Isoforms by Aldosterone and 17␤-Estradiol
Using an in vitro assay system, in which phosphatidylserine, calcium, and substrate concentrations corresponded to those yielding maximal activation, we examine the effect of aldosterone and 17␤-estradiol on human PKC␣ and PKC␦ activity. Aldosterone significantly activated PKC␣ in a concentration-dependent manner between 0.1 and 10 nM (Fig. 1A) . The EC 50 for PKC␣ activation was 0.45 Ϯ 0.05 nM, indicating that this hormone is a potent activator of PKC␣ activity. However, aldosterone had no effect on PKC␦ activity even at concentrations as high as 10 nM (Fig. 1A) . Similar effects were obtained with other mineralocorticoids such as fludrocortisone and deoxycorticosterone acetate. The relative potency for these hormones to activate PKC␣ was aldosterone ϭ fludrocortisone Ͼ deoxycorticosterone acetate Ͼ Ͼ hydrocortisone ( Table 1) .
Similarly, 17␤-estradiol had a stimulatory effect on PKC␣ activity (Fig. 1B) . This effect was concentration dependent within 0.1 and 10 nM with an EC 50 of 0.33 Ϯ 0.03 nM. In contrast to aldosterone, 17␤-estradiol did activate PKC␦ activity in a concentration-dependent manner within the same concentration range (Fig. 1B) . The EC 50 for PKC␦ activation by 17␤-estradiol was 0.41 Ϯ 0.04 nM. Similar effects were obtained for other estrogens such as estriol and estrone. The relative potency for these hormones to activate PKC␣ and PKC␦ was 17␤-estradiol Ͼ estriol Ͼ Ͼ estrone. The biologically inactive isomer 17␣-estradiol had no effect on PKC activity ( Table 1) .
Activation of PKC Isoforms by Aldosterone and 17␤-Estradiol in the Presence of 4␤-Phorbol 12,13-Dibutyrate Ester (PDBu)
To characterize aldosterone and 17␤-estradiol interactions with PKC, we examined the effect of these hormones on kinase activity induced by phorbol esters such as PDBu. Figure 2 shows the effect of a maximally stimulating concentration of aldosterone (5 nM) and 17␤-estradiol (5 nM) on the dose-response curve for PKC␣ and PKC␦ activation by PDBu. The results show an additive effect of both hormones on the PDBu-induced activation of either PKC␣ or PKC␦. The effect was independent of the concentration of PDBu. These results indicate a minimal level of allosteric interaction between these hormones and PDBu. The increased activation shown here with PDBu paired with either aldosterone or 17␤-estradiol suggests a mechanism involving a two-site mechanism of action.
Aldosterone-and 17␤-Estradiol-Induced Autophosphorylation of PKC Isoforms
To determine some of the molecular events required for steroid hormone-induced PKC activation, we examined changes in the level of PKC autophosphorylation. The autophosphorylation of PKC␣ and PKC␦ was measured using an in vitro assay with purified human PKC stimulated for 15 min with either aldosterone or 17␤-estradiol. Autophosphorylation of PKC is a step required for activation of these kinases and is often used as an index of PKC activation. Figure 3 shows the effect of increasing concentrations (0.01-10 nM) of aldosterone and 17␤-estradiol on PKC␣ and PKC␦ autophosphorylation levels. Consequent with the kinase activity assays, these hormones induced a sharp increase in the phosphorylation of both kinases. This effect was concentration dependent between 0.1 and 10 nM. The EC 50 for hormone-induced autophosphorylation of PKC␣ by aldosterone was 1.07 Ϯ 0.31 nM and 0.53 Ϯ 0.22 nM for 17␤-estradiol. Autophosphorylation of PKC␦ induced by 17␤-estradiol had an EC 50 of 0.65 Ϯ 35 nM. These results show that aldosterone and 17␤-estradiol induce autophosphorylation of PKC␣ and PKC␦ isoforms with a potency similar to that observed in the activity assays. This suggests that hormone-induced activation of PKC␣ and PKC␦ is mediated by autophosphorylation of PKC.
Binding of Aldosterone and 17␤-Estradiol to PKC Isoforms
To test our hypothesis of a direct interaction between aldosterone and 17␤-estradiol with PKC␣ and PKC␦ and to determine which PKC domains contain the binding site for these hormones, different truncation and deletion mutants of PKC␣ and PKC␦ were expressed as GST fusion proteins (Fig. 4 ). Proteins were produced using an in vitro expression system. This expression system is coupled with a redox system for formation of disulfide bonds and supplemented with a chaperone mixture for correct folding of proteins. Additionally, the reaction mixture was supplemented with 10 M ZnCl 2 for correct folding of zinc fingers contained in the C1 domain.
Full-length PKC␣-GST fusion protein showed aldosterone binding in a concentration-dependent manner with a binding affinity of 0.56 Ϯ 0.31 nM and a stoichiometry of 0.58 Ϯ 0.08 mol/mol of protein (Fig. 5) . All fusion PKC␣ mutants containing the C2 domain readily bound aldosterone with affinities and stoichiometry similar to that of the full-length kinase. Consequently, a C2-PKC␣ fusion protein also showed highaffinity aldosterone binding. Fusion proteins lacking 
Results are expressed as mean activity Ϯ SEM; a , P Ͻ 0.01; b , P Ͻ 0.05; of n ϭ 4 experiments in triplicate for each isoform and hormone. Percentage of activity is referred to the most potent mineralocorticoid (aldosterone) or estrogen (17␤-estradiol) at a maximal effective concentration of 5 nM. Absence of effect is denoted as not significant (NS) with respect to controls, and then percentage of activity is not determined (N.D.).
the C2 domain failed to bind aldosterone at any concentration. Control GST showed no aldosterone binding. Figure 5 shows saturation curves for full-length PKC␣ (A), a C1A deletion mutant PKC␣-⌬C1A (B), a C2 deletion mutant PKC␣-⌬C2 (C), and a single C2 domain C2-PKC␣ (D) and their respective Scatchard plots (E, F, G, and H). Analysis of binding data for all PKC␣-GST fusion mutants is shown in Table 2 .
Similarly, full-length PKC␣-GST fusion protein showed 17␤-estradiol binding in a concentration-dependent manner with a binding affinity of 1.03 Ϯ 0.15 nM and stoichiometry of 0.55 Ϯ 0.02 mol/mol of protein ( Fig. 6 ). All fusion PKC␣ mutants containing the C2 domain showed high specific 17␤-estradiol binding. Moreover, the C2-PKC␣ fusion protein also showed 17␤-estradiol binding with affinity constant and stoichiometry similar to that of the full-length PKC␣. Fusion proteins lacking the C2 domain failed to bind 17␤-estradiol. Figure 6 shows saturation curves for full-length PKC␣ (A), a C1A deletion mutant PKC␣-⌬C1A (B), a C2 deletion mutant PKC␣-⌬C2 (C), and a single C2 domain C2-PKC␣ (D) and their respective Scatchard plots (E, F, G, and H). Analysis of 17␤-estradiol binding data for all PKC␣-GST fusion mutants is shown in Table 2 .
Using the PKC␦-GST fusion proteins we also tested binding of 17␤-estradiol. Full-length PKC␦-GST fusion protein showed 17␤-estradiol binding in a concentration-dependent manner with a binding affinity of 0.85 Ϯ 22 nM and stoichiometry of 0.64 Ϯ 0.04 mol/ mol of protein (Fig. 7 ). Similar to aldosterone binding, all fusion PKC␦ mutants containing the C2 domain showed high specific 17␤-estradiol binding. The C2-PKC␦ fusion protein also showed 17␤-estradiol binding with similar affinity constant whereas fusion proteins lacking this domain failed to bind 17␤-estradiol. Figure 7 shows saturation curves for full-length PKC␦ (A), a C1 deletion mutant PKC␦-⌬C1 (B), a C2 deletion mutant PKC␦-⌬C2 (C), and a single C2 domain C2-PKC␦ (D) and their respective Scatchard plots (E, F, G, and H). Analysis of 17␤-estradiol binding data for all PKC␦-GST fusion mutants is shown in Table 2 . As expected, full-length PKC␦ and its mutants failed to bind aldosterone (Table 2) .
Competition assays performed on full-length PKC␣ showed that [ 3 H]aldosterone binding was displaced by aldosterone [inhibition constant (K i ), 0.41 Ϯ 0.14 nM] and 17␤-estradiol (K i , 1.33 Ϯ 0.98 nM), indicating that both hormones share the same binding site on PKC␣ (Fig. 8A ). In contrast, PDBu did not displace aldosterone binding to PKC␣, suggesting a two-site binding site model (Fig. 8A ). Similarly, [ 3 H]17␤-estradiol binding to PKC␣ was displaced by aldosterone (K i , 0.40 Ϯ 0.15 nM) and 17␤-estradiol (K i 1.38 Ϯ 0.73 nM) but not by PDBu (Fig. 8B) . In contrast, binding of [ 3 H]17␤-estradiol to full-length PKC␦ was only displaced by 17␤-estradiol (K i , 0.83 Ϯ 0.57 nM), suggesting a specific site for estrogens on this PKC isoform (Fig. 8C) . To control the binding properties of PKC␣ and PKC␦, competition assays for PDBu were carried out. [ 3 H]PDBu binding to both PKC isoforms was displaced by nonradioactive PDB with a K i of 22.2 Ϯ 2.1 nM for PKC␣ and K i 54.7 Ϯ 10.4 nM for PKC␦ (Fig. 8D) .
Binding of Aldosterone and 17␤-Estradiol to the C2 Domain of PKC␣ and PKC␦ Is Required for Hormone-Induced PKC Activation
Recombinant PKC isoforms expressed in vitro retain the binding properties of PKC expressed in eukaryotic cells but they are not catalytically active. Therefore, we examined the effect of aldosterone and 17␤-estradiol on human PKC␣ and PKC␦ expressed in Sf9 insect cells, which are known to have kinase activity. Hormone-induced PKC activity was measured in the presence of increasing concentrations of PKC␣ and PKC␦ C2 domains. Aldosterone-and 17␤-estradiol-induced PKC␣ activity was inhibited by coincubation with C2-PKC␣ in a concentration-dependent manner suggesting that sequestration of these hormones by C2-PKC␣ reduces binding and activation of full-length PKC␣ (Fig. 9A) . Similarly, 17␤-estradiol-induced PKC␦ activity was inhibited by coincubation with C2-PKC␦ in a concentration-dependent manner, suggesting sequestration of 17␤-estradiol by C2-PKC␦ reduces binding and activation of full-length PKC␦ (Fig. 9B) . In both cases, PDBu-induced PKC activity was not affected by coincubation with the C2 domain (Fig. 9, A  and B) . In contrast, coincubation with C1-domains did not affect the hormone-induced PKC activity but reduced PDBu-induced PKC activity due to sequestration of PDBu, thus preventing binding to C1 domains (Fig. 9, C and D) . These data suggest binding of aldosterone and 17␤-estradiol to the C2 domains of PKC␣ and PKC␦ is a prerequisite for kinase activation.
Hormone-Induced PKC Activation Is Independent of Steroid Hormone Receptor Expression
To determine the role of steroid hormone receptors on the aldosterone-and 17␤-estradiol-induced activation of PKC␣ and PKC␦ and the properties of this effect in cells, we examine the effect of 17␤-estradiol on PKC␣ and PKC␦ activity in estrogen receptor positive (ERϩ) MCF-7 cells and the estrogen receptor negative (ERϪ) HCC-38 cells. Kinase activity for each isoform was measured from total lysates, using specific PKC isoform inhibitors, such as HBDDE-sensitive for PKC␣ and rottlerin-sensitive for PKC␦. In HCC-38 cells a 10-min treatment with 17␤-estradiol induced a concentration-dependent increase in PKC␣ and PKC␦ activity with an EC 50 of 1.34 Ϯ 0.64 nM and 0.54 Ϯ 0.08 nM, respectively (Fig. 10A) . Similarly, in MCF-7 cells a 10-min treatment with 17␤-estradiol induced a concentration-dependent increase in PKC␣ and PKC␦ activity with an EC 50 of 0.74 Ϯ 0.16 nM and 0.51 Ϯ 0.04 nM, respectively (Fig. 10B) . Pretreatment of both cell lines with the pure antiestrogen ICI 182,780 failed to prevent the stimulatory effect of 17␤-estradiol on PKC activity even at concentrations as high as 10 M (data not shown). These data indicate that in both cell lines 17␤-estradiol caused a dose-dependent increase in both PKC␣ and PKC␦ activity, indicating ER expression is not required for the 17␤-estradiol-mediated increase in PKC activity. In order to evaluate in vivo the additive effect of steroid hormones with classic activators of PKC such as DAG and phorbol esters, we tested the effect of 17␤-estradiol on bombesin-induced PKC activity in HCC-38 cells. Bombesin is a peptide hormone that activates DAG and inositol 1,4,5-triphosphate synthesis, and intracellular Ca 2ϩ mobilization leading to PKC activation. In HCC-38 cells, bombesin increased PKC␦ activity in a concentration-dependent manner with a maximal response at 100 nM bombesin. Pretreatment with 0.1 or 1 nM 17␤-estradiol for 10 min significantly increased the bombesin-induced PKC activation even at concentrations in PKC␣ and PKC␦ were exposed to several concentrations of hormones and blotted using specific phospho-PKC antibodies; membranes were then stripped and blotted with regular PKC antibodies. Effect of aldosterone on PKC␣ (A), and effect of 17␤-estradiol on PKC␣ (B) and PKC␦ (C). Upper blot shows autophosphorylation of PKC isoforms; lower blot shows total PKC isoforms; graph shows dose-response curves for the effect. Values in graphs are mean Ϯ SEM of four experiments. *, P Ͻ 0.05; **, P Ͻ 0.01. which bombesin effect was maximal (Fig. 10C ). Aldosterone had no effect on either basal or bombesininduced PKC␦ activity (data not shown). These results suggest that 17␤-estradiol-induced PKC activation has an additive effect on other regulators of PKC, which acts through the DAG-dependent signaling pathway.
DISCUSSION
The main findings in the present study are the direct binding of PKC␣ and PKC␦ by aldosterone and 17␤-estradiol through interaction with their C2 domain, leading to autophosphorylation and activation of these kinases. These results suggests that PKC␣ and PKC␦ may serve as receptors for aldosterone and 17␤-estradiol, providing a new rapid mechanism for transducing the rapid effects of these hormones, additional to the well-known activation of PKC by membranereceptor-mediated activation of phospholipase C that leads to increases in DAG synthesis (3, 5, 8) . Because kinase activity was observed in an in vitro system containing only PKC, phospholipids, vesicles, substrates and the necessary cofactors, it can be assumed that aldosterone and 17␤-estradiol directly interact with specific binding sites on PKC␣ and PKC␦. This hypothesis is supported by the finding that other mineralocorticoids and estrogens show different potency on activating PKC␣ and that the biologically GST fusion proteins with PKC␣ (A) and PKC␦ (B) domains were generated by PCR using the indicated combination of sense (F) and antisense (R) primers, followed by ligation into pIVEX-GST plasmid, and subsequent in vitro expression. Structure of GST-PKC mutants are illustrated schematically: C1A and C1B, cysteine-rich regions; C2, calcium binding domain; C3 and C4, catalytic domains; V1-5, variable domains. For mutants containing an internal deletion the domains were amplified using the first two pairs of primers. PCR products were then fused by overlap extension PCR using the second pair of primers. Predicted molecular weights of the respective GST-PKC mutants are shown.
inactive 17␣-estradiol had no effect on the enzyme activity, indicating a degree of structural specificity rather than a nonspecific effect. Furthermore, this specificity is shown by the fact that PKC␦ was activated only by biologically active estrogens such as 17␤-estradiol and estriol but insensitive to 17␣-estradiol and aldosterone.
The finding that the level of activation achieved by a maximally stimulating concentration of these hormones in combination with the phorbol ester PDBu was higher than that achieved with any activator alone implies that aldosterone and 17␤-estradiol are not merely competing with PDBu for its binding site in the C1 domain of PKC (24-29) but rather interacting with a different binding site. To confirm this hypothesis, we performed competition assays between PDBu and aldosterone or 17␤-estradiol. We found that PDBu does not compete with either aldosterone or 17␤-estradiol binding to PKC␣ and PKC␦, confirming that these hormones do not bind to the same site for phorbol esters. These data suggest that these hormones can act both as effectors and promoters of PKC activity. This concept is supported by the in-cell studies showing an additive effect of 17␤-estradiol and bombesin, a well-known PKC agonist, on PKC activity in HCC-38 cells.
In the study presented here, we have used GST-PKC fusion proteins to determine the binding site for aldosterone and 17␤-estradiol to human PKC␣ and PKC␦. Recombinant GST-PKC fusion proteins have been widely used to study binding of activators such as DAG and phorbol esters to PKC (25) (26) (27) (28) (29) 30 ). In the vesicle assay, high-affinity hormone binding was seen with any fusion protein containing the C2 domain, but not in those lacking this domain. Furthermore, no significant differences in either hormone binding or stoichiometry were observed between any of the C2-containing mutant PKCs. Thus, the presence or absence of other PKC domains did not affect binding of these hormones to C2-containing mutant PKCs. These results clearly indicate the C2 domain is essential and sufficient for binding of aldosterone and 17␤-estradiol to a common binding site in the C2 domain of PKC␣ whereas PKC␦ exclusively binds 17␤-estradiol.
Aldosterone and 17␤-estradiol-binding stoichiometries range between 0.5 and 1.0 mol of ligand per mol of protein, suggesting a stoichiometry of 1:1 for hormone binding to PKC␣ and PKC␦. A possible concern regarding these experiments is that, in many cases, hormone-binding stoichiometries are significantly lower than 1, suggesting that, although soluble, GST fusion proteins might not necessarily be functional. However, binding stoichiometries for PKC described in this study are higher, on average, than those reported for other ligands known to bind PKC with a 1:1 stoichiometry (30), indicating the majority of soluble, purified C2-containing fusion proteins do represent functional aldosterone and 17␤-estradiol binding sites.
In recent years several studies have focused on the direct binding and activation of PKC isoforms by compounds that bind the C2 domain. The C2 domain of conventional PKC isoforms mediates calcium and phosphatidylserine binding and contains the binding site for activated C kinase receptor (31) (32) (33) . Novel PKC isoforms lack calcium-coordinating acidic residue side chains; hence novel PKCs are maximally activated by DAG and phorbol esters, without requiring calcium. Recent studies have shown that retinoic acid directly activates PKC␣ and PKC␦ upon binding of the C2 domain in two locations coincident with the two binding sites previously reported for acidic phospholipids (34-37). These observations were supported by [ 3 H]retinoic acid binding, site-directed mutagenesis, and crystallographic studies.
The traditional model of PKC activation focuses on allosteric modulation by calcium and DAG. However, more recent studies have identified a series of sequential priming phosphorylations at highly conserved serine/threonine phosphorylation motifs in all PKC isoforms that lock the enzyme in a closed, stabilized, catalytically competent and protease/ phosphatase-resistant conformation (38) (39) (40) (41) . Upon activation, PKCs are believed to undergo autophosphorylation, on a conserved proline-flanked turn motif and a hydrophobic motif, which is important for reversible PKC isoform stimulation by physiolog- ical agonists (42) . These phosphorylations on conventional PKC isoforms generally have been characterized as intramolecular autophosphorylation events (43) . In this study both aldosterone and 17␤-estradiol induced autophosphorylation of PKC␣ and PKC␦ on the hydrophobic motif. Because this event was observed in an in vitro assay the phosphorylations are likely to occur through an intramolecular mechanism. Noteworthy in this study is the fact that all the events observed (activity, autophosphorylation, and binding) are induced by nanomolar concentrations of aldosterone and 17␤-estradiol, which are consistent with the physiological concentrations of free circulating hormones (ϳ0.1-0.5 nM). Therefore, it is expected that direct binding and activation of PKC␣ and PKC␦ play a role in the physiological functions of both hormones, especially on their rapid nongenomic effects. Several studies have shown that both aldosterone and 17␤-estradiol exert rapid effects in several tissues, including PKC and MAPK activation, increase of intracellular Ca 2ϩ concentration, and regulation of ion channel activity (13) (14) (15) . In most cases, activation of PKC is critical for the activation of other rapid responses. Hence, several groups have postulated that these kinases can act as receptors for steroid hormones (44) or that hormone-induced PKC activity may act as a coregulator of a membrane receptor-mediated response (20) . PKC␣ is almost ubiquitously distributed in tissues within the body. However, the rapid responses to aldosterone and estrogen are tissue specific. Thus, other factors must be involved to confer cellular and tissue specificity for PKC␣-mediated responses. These factors include intracellular calcium, other kinases including MAPK, PDK1, and the expression levels of each PKC isoform. The latter is particularly relevant for PKC␦, which we have shown to be differentially expressed at mRNA and protein levels in male and female colonic crypts (45) . Because activation of conventional PKC isoforms depends on calcium binding, the aldosterone and 17␤-estradiol direct activation of PKC␣ must operate in concert with an increase in intracellular calcium. Several studies have shown that these hormones can increase the turnover of DAG and inositol triphosphate, leading to an increase in intracellular calcium and ultimately to PKC activation (13) (14) (15) 19) . Therefore, direct activation of PKC␣ by aldosterone and 17␤-estradiol may represent a coactivation mechanism in which they will enhance the response induced by DAG and calcium similar to the manner in which they enhance the effect of PDBu. Similarly, 17␤-estradiol could also enhance the effect of DAG-induced PKC␦ activation. However, because this PKC isoform does not require calcium, the 17␤-estradiol-induced activation of PKC␦ could take place independent of membrane receptor-mediated increase in DAG. Thus, PKC␦ can act as a receptor for 17␤-estradiol.
In conclusion, we have demonstrated for the first time a direct interaction between 17␤-estradiol and aldosterone with PKC␣ and of 17␤-estradiol with PKC␦ and have located the binding site for these hormones as being within the C2 domain. These new data support the hypothesis that discrete steroid hormone-binding sites exist in PKC isoforms with affinities for specific steroid hormones. The binding affinities are well within the physiological concentration for these hormones. Therefore, these PKC isoforms can act as receptors for steroid hor- mones and mediate cross talk with membrane receptor-mediated signaling. [1,2,6,7- 3 H]Aldosterone (80 Ci/mmol), [2, 4, 6, H]17␤-estradiol (95 Ci/mmol), and [␥-32 P]ATP (30 Ci/mmol) were from PerkinElmer (Buckinghamshire, UK). PDBu, human recombinant PKC␣ and PKC␦, histone-1, and 2,2Ј,3,3Ј,4,4Ј-hexahydroxy-1,1Ј-biphenyl-6,6Ј-dimethanol dimethyl ether (HBDDE) were from Calbiochem (Nottingham, UK). Pfu-Ultra Hot-Start DNA polymerase was from Stratagene (Cambridge, UK). Restriction enzymes, ligase, and phosphatase were from New England Biolabs (Hertfordshire, UK). Antibodies against Ser(643)-phospho-PKC␦, PKC␣, and PKC␦ were from Cell Signaling Technologies (Hertfordshire, UK), Ser(657)-phospho-PKC␣ was from Upstate (Dublin, Ireland). Protease inhibitor cocktail, horseradish peroxidase-conjugated anti-His 6 antibody, and pIVEX-GST plasmid were from Roche Applied Science (Burgess Hill, UK). All other reagents were from Sigma-Aldrich (Dublin, Ireland).
MATERIALS AND METHODS
Materials
PKC Assay
PKC activity was assayed with Triton X-100 mixed micelles, using the phosphorylation of histone-1, as described by Hannun and Bell (46) . Micelles were prepared by dissolving phosphatidylserine (2.8 mg) in chloroform in a glass tube. After evaporation of chloroform under a stream of nitrogen, 1 ml of 3% Triton X-100 (prepared fresh) was added and the mixture was sonicated. Unless stated otherwise, the reaction mixture contained 20 mM Tris (pH 7.5), 20 mM MgCl 2 , 1.0 mM CaCl 2 , 0.25 mM EGTA, 0.25 mM EDTA, 1 mM ␤-mercaptoethanol, 0.28 mg/ml phosphatidylserine, 0.3% Triton X-100, 50 M histone-1, 20 M [␥-
32 P]ATP, and 150 mU of PKC in a final volume of 25 l. Samples were incubated for 15 min at 37 C, and reactions were terminated by spotting an aliquot of reaction mixture on phosphocellulose disks (P-81, 2.3 cm, Whatman, Clifton, NJ). After washing the disks with 1% phosphoric acid, ␥-32 P incorporation into histone-1 was determined by liquid scintillation spectrometry. Non-PKC-specific activity was determined in samples incubated in the absence of the enzyme.
Cell Culture
MCF-7 and HCC-38 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown in phenol red-free DMEM with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.01 mg/ml insulin at 37 C in an atmosphere containing 5% CO 2 and 100% humidity. When confluent, cells were subcultured into six-well culture plates and grown using the same conditions as above. At confluence, cells were serum starved for 24 h and then treated with PDBu, aldosterone, or 17␤-estradiol for the required times. 
Protein Extraction and Western Blotting
Cells were lysed by hypotonic shock on ice for 45 min [Lysis buffer: 20 mM Tris, pH 7.4; 0.5% Nonidet P-40; 250 mM NaCl; 3 mM EDTA; 3 mM EGTA; leupeptin, 1 g/l; 500 mM dithiothreitol; 5 mM phenylmethylsulfonylfluoride; and complete mini EDTA-free protease inhibitor cocktail tablets (one tablet/7 ml of lysis buffer; Roche Applied Science)]. After incubation the samples were clarified at 12,000 rpm for 10 min. The cleared supernatant was collected, and the protein content was quantified by the Bradford method. Protein samples (50 g) were combined with 2ϫ sample buffer, boiled at 95 C for 5 min, and spun at 12,000 rpm for 2 min. Western blot analysis was carried out as previously described (45) . 
Autophosphorylation Assay
To determine autophosphorylation of PKC isoforms induced by aldosterone or 17␤-estradiol, recombinant human PKC isoforms (1 ng) were incubated in PKC assay mixture with nonradioactive ATP in a final volume of 25 l. Samples were treated with several concentrations of aldosterone or 17␤-estradiol (0.01-10 nM) for 15 min at 37 C. Reaction was stopped by addition of Laemli sample buffer, and samples were subjected to standard Western blot (45) with phospho-PKC␣ and phospho-PKC␦ antibodies.
Expression of GST-PKC Fusion Proteins
To generate large quantities of protein for characterization of binding, several deletion and truncation mutants of human PKC␣ and PKC␦ were expressed as amino-terminal fusion proteins with hexa-histidine (His 6 ) and GST. Briefly, specific regions of human PKC␣ and PKC␦ were amplified by PCR using the pBlueBac/PKC␣ and pBlueBac/PKC␦ clones (ATCC) containing human PKC cDNA as a template. The restriction site of all forward primers was AflIII. The restriction site of all reverse primers was EcoRV. For mutants with internal deletions, fragments of the PKC domains to be recombined were generated in separate PCRs and the amplified products were then fused by overlap extension PCR as described by Horton et al. (47) . Table 3 shows all primers used for amplification of PKC mutants. DNA amplification was carried out for 25 cycles, each at 95 C for 1 min, average primer pair melting temperature minus 5 C for 1 min, and 72 C for 2 min. The PCR products were double digested with AflIII and EcoRV, analyzed in 2% agarose gels, and isolated using Gel Extraction Kit (QIAGEN, Crawley, UK) following manufacturer's protocol. The digested PCR products were ligated into NcoI/SmaI double-digested GST-pIVEX plasmid. After ligation, DH5␣ Escherichia coli competent cells (Invitrogen, Paisley, Scotland, UK) were transformed with the plasmids. Positive clones were initially selected by restriction analysis and subsequently confirmed by DNA sequencing (MWG Biotech, Ebersberg, Germany).
In Vitro Protein Synthesis and Purification
Protein was synthesized in vitro using the rapid-translation system RTS100 E. coli Disulfide Kit (Roche Applied Science), according to the manufacturer's instructions using 200 ng of plasmid DNA per reaction. Reactions were incubated at 30 C for 12 h in an RTS ProteoMaster Instrument (Roche Applied Science). To act as a control, GST was synthesized from an empty pIVEX-GST plasmid. Proteins were purified with nickel nitrilotriacetic acid agarose spin columns (QIAGEN) according to the manufacturer's instructions. The mixture from the in vitro protein synthesis was loaded into a nickel nitrilotriacetic acid spin column and washed twice with a four-bed volume of wash buffer A (100 mM NaH 2 PO 4 ; 10 mM Tris-Cl, pH 6.3). The recombinant protein was eluted with a one-bed volume of elution buffer B (100 mM NaH 2 PO 4 ; 10 mM Tris-Cl, pH 5.9), followed by another elution with a one-bed volume of buffer C (100 mM NaH 2 PO 4 ; 10 mM Tris-Cl, pH 4.5). All buffers contained a protease inhibitor mixture. The eluted His 6 -tagged different constructs of PKC proteins were examined using standard Western blot analysis with horseradish peroxidase-conjugated anti-His 6 antibody. Purified proteins were stored at Ϫ70 C. Kazanietz et al. (48) , with minor modifications. For determination of the dissociation constants (K d ) and the number of sites (B max ) for the different PKC preparations, typical saturation curves with increasing concentrations of the radioactive ligand (between 0.01 and 10 nM) were obtained in triplicate. The assay mixture (250 l) contained 0.2 nmol GST fusion protein, 50 mM Tris-HCl (pH 7.4), 100 g/ml phospholipids, 4 mg/ml bovine IgG, 100 M CaCl 2 , and variable concentrations of ligand. The assay was carried out at 37 C for 15 min. For competition assays a fixed concentration of radiolabeled aldosterone or 17␤-estradiol (5 nM) was incubated against five to seven increasing concentrations of the competing nonradioactive PDBu and hormones.
Data Analysis
Densitometric analysis of Western blots was performed using Genetools software (Syngene, Cambridge, UK). Statistical analysis of the data was obtained using paired t test for analysis between two groups. One-way ANOVA and Tukey's post hoc test were used for multiple analyses of more than two groups. Nonlinear regression analysis of binding data was performed using Igor-Pro 3.0 software (Wavemetrics, Inc., Lake Oswego, OR). P values Յ 0.05 were considered to be significant. Data are expressed as means Ϯ SEM unless specifically stated to be from a representative experiment.
